Perjeta 420mg/14mL(pertuzumab)

Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	PERJETA
Manufacturer	U.S. production of Roche Genentech
Prescription required	Yes

Description

Perjeta 420mg/14mL(pertuzumab) is a medicine catalog record in the MediPriceHub database. Active ingredient: pertuzumab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: U.S. production of Roche Genentech. Therapeutic category: Medicine Library > Oncology Medicines > Breast Cancer Drugs. Pack information: 420mg / 14mL(30 mg / mL). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence

How to Use

Use pertuzumab under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: pertuzumab. Pack size: 420mg / 14mL(30 mg / mL). Pack unit: bottle. Manufacturer: U.S. production of Roche Genentech. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Breast Cancer Drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.

Ces informations sont fournies à titre indicatif. Demandez conseil à un professionnel de santé avant d'utiliser un médicament.